ThioBridge - A Site-Specific Conjugation Technology For The Design And Manufacture Of Next-Generation ADCs

The ThioBridge conjugation platform offers a cutting-edge solution for the development of next-generation antibody-drug conjugates (ADCs). Leveraging naturally occurring interchain disulfide bonds, ThioBridge enables stable, site-specific attachment without the need for antibody engineering. This results in highly homogeneous drug-to-antibody ratio (DAR) profiles, enhanced in vivo stability, and improved solubility compared to traditional maleimide or lysine-based technologies.

The platform has demonstrated strong performance in preclinical models, including MBRC-101, an Ephrin A5-targeting ADC showing promise in multiple cancer types. With the flexibility to incorporate cleavable or non-cleavable linkers and a wide range of payloads, ThioBridge offers a customizable toolbox for therapeutic innovation. Comparative studies show that ThioBridge ADCs exhibit reduced aggregation and greater stability, helping optimize pharmacokinetics and efficacy. This technology supports the efficient design and manufacture of complex biologics, accelerating the path to clinic.

Learn more about how ThioBridge can advance your ADC development.